Cooper Companies

The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, babies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Cooper Companies reports record revenues and optimistic outlook for growth

Cooper Companies delivered strong financial performance, exceeding revenue expectations and showcasing growth in key segments. The company is strategically positioned for sustained growth, with a focus on leveraging market opportunities and optimizing infrastructure investments. Challenges in managing growth and SKU ranges are being addressed to drive future profitability.

Cooper Companies reports record revenues and projects strong growth ahead

Cooper Companies had a stellar year, marked by record revenues and robust growth in key segments. Despite challenges in capacity and cash flow, the company is poised for continued success with confidence in overcoming obstacles. Opportunities in Myopia management, price trends, and share gains position Cooper Companies for a promising future.

Cooper Companies reports record Q1 revenues, eyes global growth opportunities

Cooper Companies delivered a strong Q1 performance with record revenues and raised full-year guidance. The company's focus on key growth areas like myopia management and daily contact lenses bodes well for future success. Addressing challenges in capacity constraints and market fluctuations will be crucial for sustained growth.

Cooper Companies (COO) reports record revenues and growth opportunities

Cooper Companies (COO) reports strong Q2 earnings with record revenues and increased guidance for fiscal 2024. Challenges include system upgrade impact and competitive uncertainties, but opportunities lie in market growth and strategic investments for future growth.

Cooper Companies (COO) excels in Q3 with record revenues and growth

Cooper Companies (COO) showcased robust financial performance in Q3 2024, driven by record revenues and earnings growth across its key segments.
While facing challenges in certain product lines, strategic investments and market-leading positions position the company well for future growth and profitability.
With a focus on innovation and operational excellence, Cooper Companies is poised to capitalize on opportunities for sustained success and market expansion.

Cooper Companies reports record revenues in Q4 2024 earnings call

Cooper Companies delivered a strong performance in Q4 2024, with record revenues and notable growth in both CooperVision and CooperSurgical segments. While facing challenges with Paragard sales, the company is focused on capitalizing on opportunities in expanding product lines and myopia management for future growth.

Cooper Companies (COO) reports record Q1 earnings and growth opportunities

Cooper Companies (COO) delivered a strong Q1 performance, with record revenues and earnings across its divisions. While facing challenges in the Fertility segment, the company remains optimistic about returning to growth for the segment. Opportunities for international expansion, product portfolio growth, and efficiency improvements position Cooper Companies for continued success. Maintaining revenue guidance for key segments and focusing on driving higher margins underscore the company's strategic priorities.

Cooper Companies excels in Q2, eyes growth amid tariff challenges

Cooper Companies demonstrated strong performance in Q2 with revenue growth and earnings increase While facing challenges from tariffs and declining hydrogel sales, the company is focused on mitigating impacts Opportunities lie in expanding myopia management portfolio and leveraging operational efficiencies for margin growth Overall, Cooper Companies remains well-positioned for continued growth and profitability

Cooper Companies reports solid Q3 performance, eyes market share growth

Cooper Companies delivered strong Q3 performance with revenue and earnings growth, focusing on MyDay and addressing challenges with Clariti. Confident in outpacing market growth, Cooper aims to gain market share through product optimization and efficiency initiatives. Strategic adjustments are being made to capitalize on opportunities in the contact lens market and drive sustainable revenue growth.

Cooper Companies reports revenue growth, eyes shareholder value enhancement

Cooper Companies delivered solid revenue growth in Q4 2025, driven by strong performances in CooperVision and CooperSurgical segments The company is focused on enhancing shareholder value through strategic initiatives and efficient capital allocation Opportunities exist for further growth in key product portfolios and markets, with a need for operational improvements to fully capitalize on strengths

Cooper Companies reports robust Q1 results and strategic growth focus

Cooper Companies delivered a strong performance in Q1, driven by revenue growth in both CooperVision and CooperSurgical segments, supported by effective capital management and strategic initiatives. While facing challenges such as operational efficiency and regional revenue softness, the company is well-positioned to capitalize on opportunities like infrastructure optimization and sales reinvestment for future growth. With a focus on maximizing shareholder value and continuous improvement, Cooper Companies remains committed to long-term success and profitability, as evidenced by raised guidance and active strategic reviews.